Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Upgraded by StockNews.com

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by equities researchers at StockNews.com to a “sell” rating in a research report issued to clients and investors on Thursday.

A number of other research analysts also recently issued reports on ARWR. Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, July 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, October 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Finally, B. Riley reiterated a “buy” rating and issued a $55.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.33.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $21.18 on Thursday. The stock has a market capitalization of $2.63 billion, a P/E ratio of -4.98 and a beta of 0.95. The company has a 50 day moving average price of $21.35 and a 200 day moving average price of $23.94. Arrowhead Pharmaceuticals has a fifty-two week low of $17.05 and a fifty-two week high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.80). The company’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.96) EPS. On average, research analysts forecast that Arrowhead Pharmaceuticals will post -4.31 EPS for the current fiscal year.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Fifth Third Bancorp lifted its position in shares of Arrowhead Pharmaceuticals by 42.5% during the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after buying an additional 354 shares during the last quarter. Arizona State Retirement System increased its stake in Arrowhead Pharmaceuticals by 2.4% in the second quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock valued at $901,000 after purchasing an additional 821 shares during the period. Commonwealth Equity Services LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 3.7% in the second quarter. Commonwealth Equity Services LLC now owns 34,663 shares of the biotechnology company’s stock valued at $901,000 after buying an additional 1,250 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Arrowhead Pharmaceuticals by 1.1% during the second quarter. The Manufacturers Life Insurance Company now owns 149,156 shares of the biotechnology company’s stock worth $3,877,000 after buying an additional 1,677 shares during the period. Finally, State of Alaska Department of Revenue grew its holdings in shares of Arrowhead Pharmaceuticals by 16.1% during the first quarter. State of Alaska Department of Revenue now owns 13,437 shares of the biotechnology company’s stock worth $384,000 after buying an additional 1,860 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.